Piper Jaffray Reiterates Neutral on Somaxon Pharmaceuticals, Reduces PT to $2

by Emily Austin, Benzinga Staff Writer
August 3, 2011 8:49 AM | 13 seconds read |
Piper Jaffray reiterated its Neutral rating on Somaxon Pharmaceuticals SOMX. At the same time, the rating agency reduced its price target on the company's stock from $2.50 to $2. On Tuesday, SOMX closed the day at $1.51.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Price TargetReiterationAnalyst RatingsHealth CarePharmaceuticalsPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!